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Abstract 
Osteoarthritis (OA) is a disease involving inflammation and subsequent degeneration of 
joint tissues. The disease progresses with time-dependent stages of degeneration, loss 
and remodelling of the extracellular matrix (ECM) of articular cartilage, and 
phenotypical changes in the chondrocytes. Currently, OA is diagnosed clinically late in 
the disease process when irreversible damages to the cartilage are already evident. An 
understanding of the disease mechanism in the early stage of the inflammatory process 
is therefore crucial if early stage diagnostic biomarkers are to be identified. 
The aim of this thesis was to follow cartilage changes during normal development 
and interleukin (IL)-ȕ-induced inflammation. Biomarkers of early OA are needed and 
a prerequisite for finding unique molecular markers is an understanding of the cellular, 
genetic and molecular events that occur in chondrogenic development and 
inflammation. The hypothesis was that inflammation-related events occur at specific 
time points which can be used to differentiate stages of OA from each other. 
The localisation of proteins in developing equine cartilage was studied using 
immunohistochemistry with the aim of characterising different phenotypes of 
chondrocytes and their surrounding ECM. The expression of matrix molecules, Notch 
signalling components, and the stem cell-indicating factor Stro-1 showed spatial 
changes in expression and localisation during maturation.  
Equine articular cartilage explants stimulated with IL-ȕwere used as an in vitro 
model mimicking the IL-ȕ-induced inflammation that occurs during the progression of 
equine OA. The longitudinal release induced by IL-ȕof molecules from the explants 
into the media was studied using quantitative proteomics and the gene expression in the 
cartilage explants was evaluated using microarray. The secretion of ECM components 
and inflammatory mediators followed a time-dependent pattern. Microarray analysis 
also revealed time-dependent differences in gene expression related to inflammation, 
ECM, and phenotype. 
The data from this thesis contribute to the understanding of cellular, genetic and 
molecular events in the progression of OA. Stimulation of equine articular cartilage 
explants with IL-ȕLQGXFHVUHOHDVHRISURWHLQVDQGDOWHUHGJHQHH[SUHVVLRQLQDWLPH-
dependent pattern. This in vitro model has the potential to aid in testing medical 
treatments of equine OA, prior to testing in live animals, thereby minimising the use of 
research animals. 
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1 Introduction 
1.1 General background 
Lameness is a common clinical problem in horses (Penell et al., 2005; Jeffcott 
et al., 1982), with impact on economy as well as animal welfare. Osteoarthritis 
(OA) affecting synovial joints is a common cause of lameness and poor 
performance in horses (Kidd et al., 2001). The joints most commonly affected 
by OA are the fetlock joints followed by the carpal joints (McIlwraith et al., 
2012; Penell et al., 2005). Multiple factors contribute to the initiation and 
progression of the disease with inflammation and abnormal mechanical load 
considered important factors in equine OA (Kidd et al., 2001). Synovial joints 
include components such as articular cartilage, subchondral bone, synovial 
fluid, synovial membrane, joint capsule and ligaments (Frisbie, 2006; Archer et 
al., 2003). OA affects the whole joint and includes features such as 
inflammation, with degeneration of articular cartilage, and subchondral bone 
sclerosis. The disease progress from early to late stages of OA including time-
dependent stages of degeneration, loss and remodelling of the extracellular 
matrix (ECM) of articular cartilage, and phenotypical changes in the 
chondrocytes. The phenotypes of chondrocytes during OA share similarities 
with those observed during the development of articular cartilage (Goldring & 
Goldring, 2007). Knowledge about the cellular, genetic and molecular changes 
during the progression of OA is essential for the possibilities to identify 
markers of OA stages and to find disease-modifying treatments. 
1.2 Articular cartilage 
Articular cartilage is hyaline cartilage that constitutes the joint surface. The 
major function of the articular cartilage is to provide a smooth, frictionless area 
for transmission of load within the joint. The articular cartilage comprises 
chondrocytes surrounded by ECM and does not include vessels, nerves or 
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lymphatics (Sophia Fox et al., 2009; Frisbie, 2006; Buckwalter et al., 2005). 
The ECM is important for the structure and function of the articular cartilage 
and has water, collagens and proteoglycans as its main components. Water 
constitutes up to 70-80% of the cartilage wet weight and is responsible for 
functions such as transport of nutrients, lubrication and the ability of cartilage 
to withstand mechanical load. The remaining dry weight is composed of about 
50% collagens that provide tensile strength and 35% proteoglycans that 
provide resistance to compressive forces. The remaining portion of the dry 
weight is composed of non-collagenous proteins and glycoproteins with 
various functions in the organisation, assembly and maintenance of the ECM 
(Sophia Fox et al., 2009; Frisbie, 2006). The articular cartilage can be divided 
into different zones. The superficial zone, comprising the surface zone and the 
upper zone, is closest to the joint cavity followed by the middle and the deep 
zones. The calcified cartilage closest to the subchondral bone is separated from 
the deep zone by the tidemark (Figure 1) (Pritzker & Aigner, 2010). The 
average thickness of equine cartilage is 0.86 mm and 0.87 mm in the fetlock 
and carpal joints, respectively (Lee et al., 2014). 
 
Figure 1. Zones of articular cartilage. The superficial zone comprising the surface zone and the 
upper zone are located closest to the joint cavity and contain collagen fibres aligned parallel to the 
joint surface. The surface zone does not contain chondrocytes; however, the upper zone contains 
flattened chondrocytes aligned parallel to the joint surface. The middle zone contains less-
organised collagen fibres and chondrocytes in groups whereas the deep zone is characterised by 
chondrocytes and collagen fibres perpendicular to the joint surface. The tidemark is the border 
between uncalcified and calcified cartilage. Chondrocytes and collagen fibres in the calcified 
cartilage are aligned as in the deep zone and located closest to the subchondral bone (Pritzker & 
Aigner, 2010). 
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1.2.1 Chondrocytes 
Chondrocytes are the only cell type present in articular cartilage. The major 
functions of chondrocytes are to synthesise and maintain the ECM and thereby 
contribute to growth and functionality of the articular cartilage (Archer & 
Francis-West, 2003; Stockwell, 1978). Chondrocytes respond to mechanical 
stimuli by altering gene expression and metabolism (McCulloch et al., 2014; 
Chen et al., 2013a; Guilak et al., 2004; Grodzinsky et al., 2000; Freeman et al., 
1994). Rounded chondrocytes are present in normal cartilage, but the shape is 
more flattened towards the articular surface. The cells contain a nucleus and 
cytoplasm with rough endoplasmic reticulum and Golgi apparatus as major 
organelles although lysosomes, mitochondria, filaments, glycogen and lipid 
deposits are also present. Glycolysis is the major energy source for the 
chondrocyte and nutrients and metabolites diffuse through the articular surface 
(Archer & Francis-West, 2003; Stockwell, 1978). Chondrocytes in the articular 
cartilage express gap junction proteins and can connect to each other via cell-
to-cell interactions (Mayan et al., 2013). 
1.2.2 Extracellular matrix (ECM) 
The chondrocytes are surrounded by the ECM which can be divided into 
different domains (Figure 2). The pericellular matrix surrounds the 
chondrocyte and the term chondron refers to one or more chondrocytes and 
their pericellular matrix. The territorial matrix surrounds the chondrons and the 
interterritorial matrix is located in between the territorial matrix of different 
chondrons (Pritzker & Aigner, 2010). The content and organisation of matrix 
molecules varies with depth from the surface as well as proximity to 
chondrocytes (Figure 2) (Umlauf et al., 2010; Heinegård, 2009; Buckwalter et 
al., 2005; Pearle et al., 2005).  
14
 
Fi
gu
re
 2
. L
oc
at
io
n 
an
d 
or
ga
ni
sa
tio
n 
of
 so
m
e 
of
 th
e 
im
po
rta
nt
 e
xt
ra
ce
llu
la
r m
at
rix
 (E
C
M
) m
ol
ec
ul
es
 in
 a
rti
cu
la
r c
ar
til
ag
e.
 T
he
 p
er
ic
el
lu
la
r m
at
rix
 is
 lo
ca
te
d 
cl
os
es
t t
o 
th
e 
ch
on
dr
oc
yt
e 
fo
llo
w
ed
 b
y 
th
e 
te
rr
ito
ria
l a
nd
 in
te
rte
rr
ito
ria
l m
at
rix
 a
t f
ur
th
er
 d
is
ta
nc
e.
 R
ec
ep
to
rs
 a
re
 lo
ca
te
d 
at
 th
e 
ce
ll 
su
rf
ac
e 
an
d 
th
e 
di
st
rib
ut
io
n 
of
 
m
at
rix
 c
om
po
ne
nt
s v
ar
ie
s w
ith
in
 th
e 
su
rr
ou
nd
in
g 
do
m
ai
ns
. A
da
pt
ed
 fr
om
 H
ei
ne
gå
rd
, D
. (
20
09
) P
ro
te
og
ly
ca
ns
 a
nd
 m
or
e 
– 
fr
om
 m
ol
ec
ul
es
 to
 b
io
lo
gy
. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f E
xp
er
im
en
ta
l P
at
ho
lo
gy
, 9
0(
6)
, p
p.
 5
75
-5
86
.  
Ill
us
tr
at
io
n:
 P
on
tu
s 
A
nd
er
ss
on
Co
lla
ge
n 
II 
/ X
I
Ch
on
dr
oa
dh
er
in
In
te
gr
in
Ch
on
dr
oc
yt
e
Pe
rle
ca
n
CD
44
H
ya
lu
ro
na
n
G
ly
pi
ca
n
Ag
gr
ec
an
Ag
gr
ec
an
H
ya
lu
ro
na
n
Li
nk
pr
ot
ei
n
Fi
br
on
ec
tin
Sy
nd
ec
anPe
ri
ce
llu
la
r
Te
rr
it
or
ia
l
In
te
rt
er
ri
to
ri
al
Collagen IX
M
at
ril
in
Co
lla
ge
n 
II 
/ X
I
CO
M
P
D
ec
or
in
Fi
br
om
od
ul
in
15 
Collagens 
The major constituent of the ECM dry weight is collagen with several types 
present in mature cartilage. Collagen type II is the major one in mammals 
whereas collagen types III, VI, IX, X, XI, XII, and XIV are present in different 
domains in smaller amounts (Buckwalter et al., 2005; Eyre, 2002). All 
collagens are triple helices composed of threHĮ-chains which can be similar 
(homotrimers) or different from each other (heterotrimers). Every third 
position on the polypeptide chains is a glycine residue with importance for the 
assembly of the triple helix. The other residues, their modifications, and the 
lengths of the chains vary between different types of collagens (Gelse et al., 
2003). Fibril-forming collagens such as collagen types II, III, and XI form 
fibrils that are organised into a framework stabilized by other matrix molecules 
(Buckwalter et al., 2005; Gelse et al., 2003). The organisation of the fibrils 
differs in different zones of the articular cartilage. The superficial zone 
contains densely packed, thin collagen fibrils aligned parallel to the surface 
whereas the middle zone contain thicker fibrils loosely packed in a less-
organised oblique arrangement. The alignment of the fibrils in the deep and 
calcified zones is perpendicular to the articular surface (Pritzker & Aigner, 
2010; Pearle et al., 2005; Eyre, 2002). 
Collagen type II, composed of WKUHHLGHQWLFDOĮ-chains, is the most abundant 
type of collagen in all zones of articular cartilage where it constitutes about 
90% of the collagen content in mature articular cartilage. Collagen types IX 
and XI bind covalently to collagen type II and form heteromeric fibrils as a 
part of the ECM framework. Collagen type IX belongs to the fibril-associated 
collagens with interrupted triple helices (FACIT) and is a heterotrimer of the 
WKUHH FKDLQV Į Į DQG Į. Collagen type XI is a fibril-forming collagen 
FRPSRVHGRI WKUHHĮ-chains—ĮDQGĮDUHHQFRGHGE\ WKHJHQHVCOL11A1 
and COL11A2 DQG WKHĮ-chain cKDLQ LVHQFRGHGE\ WKHVDPHJHQHDV WKHĮ-
chains of collagen type II (Buckwalter et al., 2005; Gelse et al., 2003; Eyre, 
2002). Another collagen found linked to collagen type II is collagen type III 
which is a minor component of articular cartilage (Eyre, 2002). Collagen type 
VI is a microfibrillar collagen predominantly located close to the chondrocytes. 
Other collagens present in articular cartilage are collagen types XII and XIV 
which are FACIT collagens attached to fibril surfaces. Collagen type X is 
present around cells in the cartilage bone interface and around hypertrophic 
cells (Gelse et al., 2003; Eyre, 2002; Poole, 1997). 
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Proteoglycans 
The second largest constituent of the ECM dry weight is proteoglycans which 
are characterised by glycosaminoglycan (GAG) chains covalently linked to a 
core protein. Extracellular proteoglycans include proteins such as aggrecan and 
small leucine rich proteoglycans/proteins (SLRPs) and pericellular 
proteoglycans, e.g., perlecan (also called heparan sulphate proteoglycan 2, 
HSPG2). Proteoglycans can also be anchored to the cell surface, either as 
transmembrane proteins such as chondroitin sulphate proteoglycan 4 (CSPG4) 
and the syndecans, or anchored to glycosylphosphatidylinositol, e.g., the 
glypicans. The only intracellular proteoglycan is serglycin (Iozzo & Schaefer, 
2015; Heinegård, 2009; Sophia Fox et al., 2009; Roughley, 2006; Hardingham 
& Fosang, 1992). 
Aggrecan is the most abundant proteoglycan forming large aggregates 
together with hyaluronan (HA). The core protein of aggrecan can be divided 
into the domains G1, G2 and G3. Interaction between aggrecan and HA occurs 
at the G1 domain and is stabilized by a link protein. G1 is located in the amino 
terminus of the core and connected to G2 via an inter-globular domain. The 
GAG chains are located between the G2 domain and the G3 domain at the 
carboxy terminus of the core protein. Keratan sulphate side chains are located 
closest to the G2 region and chondroitin sulphate side chains are located 
closest to the G3 domain. The G3 domain is important for post-translational 
processing and secretion of aggrecan (Roughley, 2006; Kiani et al., 2002). 
Presence of specific cleavage sites allows enzymatic cleavage of the core 
protein and release of aggrecan fragments (Kiani et al., 2002). The globular 
domains are highly conserved between species whereas the extending domains 
are less conserved. (Caporali et al., 2015; Kiani et al., 2002). The overall 
amino acid identity between human and equine aggrecan is 65.8% (Caporali et 
al., 2015). 
SLRPs are matrix molecules containing repeats of leucine residues which 
allow binding to collagen fibrils. These molecules are involved in formation 
and stabilization of the collagen network as well as in interactions between 
matrix components (Kalamajski & Oldberg, 2010; Heinegård, 2009; Schaefer 
& Iozzo, 2008). SLRPs can be divided into five classes based on their 
structural and functional properties. Class I includes biglycan, decorin, asporin, 
extracellular matrix protein 2 (ECM2) and extracellular matrix protein X 
(ECMX); class II includes fibromodulin, lumican, prolargin (also called 
proline/arginine-rich end leucine-rich repeat protein, PRELP), keratocan and 
osteoadherin; class III includes epiphycan, opticin and osteoglycin; class IV 
includes chondroadherin, nyctalopin and tsukushi; and, class V includes 
podocan and podocan-like 1 (Iozzo & Schaefer, 2015; Ni et al., 2014).  
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Lubricin (also called proteoglycan 4), is a glycoprotein with a protective 
role in lubrication of articular joints as it reduces friction and chondrocyte 
apoptosis (Waller et al., 2013; Rhee et al., 2005). Chondrocytes in the 
superficial zone synthesize and secrete lubricin (Schumacher et al., 1994). 
The pericellular proteoglycan perlecan, initially isolated from basement 
membranes (Hassell et al., 1980), provides cell adhesion to the matrix 
(Sundarraj et al., 1995), and is involved in mechanotransduction (Wilusz et al., 
2012; Vincent et al., 2007), cartilage development (Arikawa-Hirasawa et al., 
1999), angiogenesis (Aviezer et al., 1994), and growth factor signalling 
(Chuang et al., 2010; Aviezer et al., 1994). 
Transmembrane syndecans are heparan sulphate proteoglycans with various 
biological functions such as binding to growth factors, acting as co-receptors, 
and mediating endocytosis (Iozzo & Schaefer, 2015; Choi et al., 2011). 
Cleavage by peptidases such as matrix metallopeptidases (MMPs) leads to 
subsequent shedding of syndecans. This results in a change in surface receptor 
dynamics and a soluble ectodomain. The ectodomain can exert biological 
effects or function as a competitive inhibitor of other syndecans 
(ManonǦJensen et al., 2010). 
Glypicans are other heparan sulphate proteoglycans that regulate biological 
signalling pathways including those involving Wnts, bone morphogenic 
proteins (BMPs), and fibroblast growth factors (FGFs). Glypicans are attached 
to the outer surface of the cell by a glycosylphosphatidylinositol anchor and 
can be released from the surface by lipase cleavage (Filmus et al., 2008). 
The intracellular proteoglycan serglycin had been detected in chondrocytes 
(Zhang et al., 2010). Serglycin allow storage of compounds in granules inside 
the cells. The stored components can be released through regulated secretion 
initiated by, for example, inflammatory reactions. Serglycin can be secreted 
either constitutively or initiated by agents such as inflammatory stimuli (Kolset 
& Pejler, 2011). 
Non-collagenous proteins 
In addition to collagens and proteoglycans, there are several other proteins 
such as non-collagenous proteins and glycoproteins important for the structure 
and function of the ECM (Sophia Fox et al., 2009).  
Cartilage oligomeric matrix protein (COMP, also called thrombospondin 5), 
consist of 5 subunits linked together at their amino terminus. The carboxy 
terminus of each subunit can bind to other components of the ECM and thereby 
mediate matrix assembly and stability (Heinegård, 2009). COMP is considered 
a catalyst in collagen fibril formation due to its ability to assemble free 
collagens into fibrils (Halász et al., 2007). 
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Matrilins, a group of non-collagenous proteins, bind to many other 
molecules of the ECM such as collagens, COMP, biglycan and decorin, and 
thereby mediate interactions important for the cartilage integrity (Klatt et al., 
2011; Heinegård, 2009; Deák et al., 1999). Additionally it is suggested that 
matrilins are involved in mechanical stimulation of chondrocytes as the levels 
of matrilins affect the responsiveness of chondrocytes to mechanical load 
(Kanbe et al., 2007). Increased gene expression of matrilin has also been seen 
as a response to mechanical stimulation (Wu & Chen, 2000). 
Fibronectin is a glycoprotein protein present in many tissues and involved 
in interactions between cells and other molecules. Cellular processes such as 
adhesion, migration, differentiation and proliferation are influenced by signal 
transduction induced by fibronectin (Romberger, 1997). 
Cartilage intermediate layer protein (CILP) is a non-collagenous protein 
identified in middle and deep zones of articular cartilage. The protein is 
synthesised by chondrocytes and located in the interterritorial matrix where it 
is suggested to be involved in maintenance of the tissue structure (Lorenzo et 
al., 1998a; Lorenzo et al., 1998b).  
Receptors for matrix components 
Communication between chondrocytes and their surrounding ECM is mediated 
through cell surface receptors. Signalling initiated by ECM components can 
affect the behaviour of the cell leading to changes in phenotype and altered 
metabolism (Loeser, 2014; Kim et al., 2011; Knudson & Loeser, 2002). In 
addition to the above-mentioned proteoglycans; syndecans and glypicans, there 
are many other receptors with importance for cartilage homeostasis.  
Cluster of differentiation 44 (CD44) is a transmembrane receptor containing 
a cytoplasmic tail, a hydrophobic transmembrane domain, and an extracellular 
domain (Goldstein et al., 1989). CD44 is the primary receptor for HA (Aruffo 
et al., 1990), but can also bind to other molecules such as lubricin (Al-Sharif et 
al., 2015) and serglycin (Toyama-Sorimachi et al., 1995). CD44 is responsible 
for endocytosis and degradation of HA in chondrocytes (Hua et al., 1993). 
Other functions of HA binding to CD44 include inhibition of interleukin (IL)-
ȕ LQGXFHG SURGXFWLRQ RI 003V (Julovi et al., 2004) and assembly of the 
pericellular matrix (Knudson, 1993). 
,QWHJULQVDUH WUDQVPHPEUDQHJO\FRSURWHLQVFRPSRVHGRIĮ- DQGȕ-subunits 
that mediate interactions between chondrocytes and the ECM. Integrin 
signalling regulates cellular responses such as proliferation, differentiation, 
survival, and matrix remodelling (Loeser, 2014; Forsyth et al., 2002; Giancotti 
& Ruoslahti, 1999). ,QWHJULQ Įȕ Ls the primary collagen type II-binding 
integrin (Camper et al., 1998). Other ECM molecules such as matrilin, 
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chondroadherin, COMP and fibronectin can also bind to the integrins (Loeser, 
2014). Integrins also act as mechanoreceptors involved in mechanotransduction 
(Chen et al., 2013a; Shimizu et al., 2004; Wright et al., 1997). 
1.3 Development of synovial joints 
Synovial joints develop as a result of chondrogenesis that starts with formation 
of a cartilage model. This is followed by endochondral ossification where the 
cartilage model is gradually replaced by bone. Recruitment and condensation 
of mesenchymal cells lead to formation of the interzone and differentiation of 
the cells into chondrocytes during chondrogenesis (Khan et al., 2007; Goldring 
et al., 2006). A primary ossification centre is formed in the centre of the 
diaphysis of the cartilaginous bone. This is followed by the formation of 
secondary ossification centres in the epiphyses, leaving cartilaginous growth 
plates between the primary and secondary ossification centres. Epiphyseal 
articular cartilage covers the surface ends of the bone towards the joint cavities 
(Figure 3) (Mackie et al., 2011).  
 
Figure 3. The development of long bones. (a) Cartilage model that will be gradually replaced by 
bone during endochondral ossification. (b) Formation of the primary ossification centre in the 
diaphysis followed by (c) formation of the secondary ossification centres in the epiphyses. Blood 
vessels are invading the tissue. (d) Further ossification gradually replaces the vascular growth 
cartilage with bone leaving the avascular articular cartilage at the ends of the bone. 
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The replacement of cartilage by bone occurs as a process of endochondral 
ossification when resting chondrocytes proliferate and become hypertrophic 
cells that undergo apoptosis (Khan et al., 2007; Goldring et al., 2006). Hence, 
the growth plate is divided into resting, proliferative, hypertrophic and 
ossification zones (Figure 4) (Behonick & Werb, 2003). In contrast to mature 
articular cartilage, which is avascular, there are vessels invading the tissue 
during development. Vascularisation is important during endochondral 
ossification as a source of factors influencing growth and differentiation of 
cells (Walzer et al., 2014; Gerber & Ferrara, 2000; Bittner et al., 1998). The 
processes occurring during joint development are regulated by factors such as 
interactions between matrix and cells, growth and differentiation factors, and 
various signalling pathways (Goldring et al., 2006; Archer et al., 2003). The 
ECM molecules are important regulators with the ability to signal directly to 
the cells in the microenvironment as well as affect signalling molecules and 
thereby signal to surrounding cells. The chondrocytes in the different zones can 
additionally produce different types of ECM molecules as a response to various 
stimuli and thereby affect the organisation of the surrounding ECM. One 
example is that the hypertrophic cells specifically synthesise collagen type X 
(Behonick & Werb, 2003).  
 
Figure 4. Zones of the growth plate. Chondrocytes in the resting zone start to proliferate, become 
hypertrophic, and undergo apoptosis leading to ossification of the cartilage into bone. 
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The perichondrial groove of Ranvier is a fibrochondrosseous structure 
encircling the growth plate (Figure 5). The structure was first described by 
Ranvier in 1873 and suggested to be important in the development of bones 
(Shapiro et al., 1977). Cells with different morphology—including progenitor 
cells—have been identified in the zone of Ranvier (Shapiro et al., 1977) and 
further studies have identified  a stem cell niche in the same area (Karlsson et 
al., 2009). A potential migration route—containing transit amplifying cells 
from the zone of Ranvier towards the articular cartilage—has also been 
characterised (Henriksson et al., 2013). 
 
Figure 5. Location of the zone of Ranvier (arrow) in growth cartilage (left) and in equine growth 
cartilage stained with haematoxylin and eosin (right). SOC, secondary ossification centre; GP, 
growth plate; POC, primary ossification centre. Schematic drawing (left) by Pontus Andersson, 
modified from Paper III (Löfgren et al., 2014), and reproduced with permission from the 
publisher. 
Progenitor cells identified in articular cartilage have the potential to be 
involved in growth and repair of cartilage (Alsalameh et al., 2004; Dowthwaite 
et al., 2004; Hayes et al., 2001). These cells are not fully characterised and 
there is no definitive marker for their identification in cartilage tissue. There 
are, however, a number of stem cell-related-markers that alone or in 
combination with each other can be used to characterise the progenitor cells 
(Jiang & Tuan, 2015). 
Stro-1 is a potential stem cell-marker which has been identified in human, 
equine, rabbit and murine articular cartilage (Ozbey et al., 2014; McCarthy et 
al., 2012; Otsuki et al., 2010; Williams et al., 2010; Grogan et al., 2009; 
Karlsson et al., 2009), and additionally in the perichondrial groove of Ranvier 
in rabbits (Karlsson et al., 2009). 
SOC
GP
SOC
POC
GP
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Notch1 is a cell surface receptor detected in progenitor cells isolated from 
bovine, human and equine articular cartilage (McCarthy et al., 2012; Williams 
et al., 2010; Dowthwaite et al., 2004). Signalling through the Notch1 receptor 
is involved in the development of various cell types including chondrocytes 
(Williams et al., 2009; Karlsson et al., 2007; Hardingham et al., 2006; 
Dowthwaite et al., 2004; Hayes et al., 2003; Watanabe et al., 2003). Notch1 is 
one of four Notch receptors (Notch1-4) in mammals. The signalling is 
mediated through binding of ligands to the receptors, leading to translocation 
of the Notch intracellular domain into the nucleus of the cells and transcription 
of target genes such as the hairy enhancer of split (Hes) family. The largest 
family of ligands contains a Delta/Serrate/LAG2 (DSL) domain and includes 
Jagged1, Jagged2, Delta-like (Dll)1, Dll3 and Dll4 in mammals (Wang, 2011; 
D’Souza et al., 2010; Kopan & Ilagan, 2009). The DSL ligands signal through 
canonical Notch signalling in which the ligand is located on a signal-sending 
cell in proximity to a signal-receiving cell expressing the Notch receptor. 
However, there are several secreted or membrane bound proteins lacking DSL 
domains that modify Notch signalling. These proteins are referred to as non-
canonical ligands and include several proteins that act in a context-dependent 
matter (Wang, 2011). 
Epidermal growth factor-like domain 7 (EGFL7) is a non-canonical Notch 
signalling modifier that binds Notch receptors and inhibits Jagged1 mediated 
signalling (Schmidt et al., 2009). EGFL7 is a secreted protein with known roles 
in vascular development and cell migration (Campagnolo et al., 2005; Parker et 
al., 2004; Soncin et al., 2003). Reduced proliferation and self-renewal have 
been observed in neural stem cells as a result of EGFL7 mediated reduction in 
Notch signalling (Schmidt et al., 2009). 
1.4 Osteoarthritis (OA) 
OA involves the entire joint with morphologic changes such as articular 
cartilage degradation, synovitis, and subchondral bone remodelling with 
sclerosis and osteophyte formation (Loeser et al., 2012). OA in horses presents 
similarities as well as differences to human OA. Equine OA often affects 
synovial joints subjected to high and frequent mechanical load during racing. 
Single event trauma, as well as poor conformation of the joints causing focal 
high mechanical load, are other causes of equine OA (Kidd et al., 2001). These 
factors are also relevant for the initiation of OA in humans, although age is also 
a major factor (Goldring & Goldring, 2007). The similarities between OA in 
athletic horses and humans make the horse a suitable model to study the 
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pathogenesis of naturally occurring OA in humans (McIlwraith et al., 2012; 
Schlueter & Orth, 2004). 
1.4.1 Initiation and progression of OA 
In normal joints, there is a balance between anabolic and catabolic processes. 
In OA, these processes are in imbalance leading to initiation and progression of 
the disease. OA always includes inflammation and subsequent degeneration of 
the articular cartilage in the affected joints. This results in destruction of the 
connective tissues, with clinical signs such as joint swelling and pain, with 
subsequent lameness (Goldring & Goldring, 2007; Schlueter & Orth, 2004; 
Kidd et al., 2001). Macroscopic changes characteristic for OA in articular 
cartilage include wear lines and erosions ranging from partial- to full-thickness 
(Figure 6) (McIlwraith et al., 2010).  
 
Figure 6. Macroscopical lesions in articular cartilage from the distal third metacarpal bone of the 
fetlock joint showing a) wear lines, and b) erosions.  
Late-stage OA also includes subchondral bone remodelling and osteophyte 
formation (Loeser et al., 2012). Mechanical load—considered the major factor 
leading to equine OA—affects the activity of the chondrocytes. Although 
excessive mechanical load is a risk factor for OA development, some load is 
necessary to maintain the normal homeostasis of the joints (Guilak et al., 
2004). Moderate load leads to increased ECM synthesis and decreases 
expression of pro-inflammatory and catabolic genes. In contrast, abnormally 
high load results in apoptosis and necrosis of chondrocytes, ECM catabolism, 
and synthesis of inflammatory mediators (Sanchez-Adams et al., 2014). The 
fragments released during ECM degradation, and the inflammatory mediators 
in combination with continued abnormal load, further progress the disease 
leading to continued degradation, inflammation and  phenotypical changes of 
the chondrocytes (Goldring & Goldring, 2007). Fragments of collagen type II 
and fibronectin induce expression of matrix-degrading enzymes; this leads to 
further degradation of the ECM (Guo et al., 2009; Homandberg et al., 1997). 
Fragments of fibronectin are also involved in the progression of OA through 
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induction of pro-inflammatory cytokines (Homandberg et al., 1997). The 
balance between pro-inflammatory and anti-inflammatory cytokines as well as 
the level of growth factors and released matrix fragments influence the 
progression of the disease (Goldring, 2000). See a summary of the progression 
of OA in figure 7. 
 
Figure 7. The initiation and progression of OA. Causative factors are listed above and changes
occurring during the different stages of OA are listed below. Adapted from Goldring, M. B. and 
Goldring, S. R. (2007) Osteoarthritis. Journal of Cellular Physiology, 213(3), pp. 626-634.  
1.4.2 Inflammation 
Inflammation during the progression of OA involves several mediators 
produced by synoviocytes and chondrocytes. The cytokines IL-ȕ DQd tumor 
necrosis factor (TNF)-Į DUH FRQVLGHUHG NH\ SOD\HUV LQ WKH 2$-related 
inflammation. Inflammatory mediators, released matrix products, and external 
influences such as high mechanical load, stimulate the cells to release 
cytokines. These cytokines act on cells nearby or on the cells producing them 
(Goldring, 2000; Westacott & Sharif, 1996). In addition to IL-ȕDQG71)-Į, 
there are several other pro-inflammatory cytokines involved in OA-associated 
inflammation. These include IL-Į ,/-6, leukemia inhibitory factor (LIF), 
oncostatin-M, IL-15, IL-17, IL-18 and IL-21. Some of them, such as IL-6, LIF 
and oncostatin-M, are regulatory cytokines. There are also a number of anti-
inflammatory cytokines such as IL-4, IL-10, IL-11, IL-13, IL-1 receptor 
antagonist (IL-1Ra) and interferon-Ȗ ZKLFK FRXQWHUDFW WKH SUR-inflammatory 
actions (Kapoor et al., 2011; Fernandes et al., 2002; Goldring, 2000). The 
actions of the pro-inflammatory cytokines can also be counteracted by growth 
factors promoting synthesis of new matrix. These growth factors include 
proteins in the families of transforming growth factor-ȕ %03V, FGFs and 
insulin-like growth factor-I (Goldring, 2000).  
Initiation Early OA Progression Late OA
Mechanical load
 Structural
changes in ECM
 Activation or 
inactivation of 
signalling
pathways
 Inflammation
 Pro-inflammatory
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and degradation of 
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chondrocytes
 Angiogenesis
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 Apoptosis
 Osteophyte formation
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25 
Other mediators of inflammation are the chemokines which increase ECM 
degradation through MMPs and induce phenotypic changes (Mazzetti et al., 
2004; Merz et al., 2003; Borzì et al., 2000). The acute phase response with 
increased levels of proteins such as C-reactive protein and serum amyloid A 
(SAA) are also part of the inflammatory process in OA (de Seny et al., 2013; 
Sipe, 1995). The pathogenesis of OA also involves the complement system 
triggered by inflammation, and released matrix components. Activation of 
complement leads to further production of matrix-degrading enzymes and 
inflammatory mediators (Wang et al., 2011).  Fibromodulin, chondroadherin 
and osteoadherin are matrix molecules that activate the classical complement 
pathway and, to a lesser extent, the alternative pathway (Sjöberg et al., 2009a; 
Sjöberg et al., 2005). The matrix molecules also has the ability to inhibit the 
complement cascade through binding to inhibitors of the signalling (Sjöberg et 
al., 2009b). COMP regulates the complement cascade by activation of the 
alternative pathway and by inhibition of the classical and lectin pathways 
(Happonen et al., 2010).  
IL -ȕ 
IL-ȕ, a member of the IL-1 family associated with inflammation (Van de 
Veerdonk & Netea, 2013), is detected in synovial fluid, synovial membrane, 
cartilage and subchondral bone in OA joints (McNulty et al., 2013; Kapoor et 
al., 2011; Saha et al., 1999; Towle et al., 1997). Active IL-ȕLVIRUPHGDIWHU
cleavage of a 31 kDa inactive IL-ȕ precursor to yield the 17.4 kDa active 
product (Black et al., 1988). The peptidase IL-ȕ FRQYHUWLQJ HQ]\PH, also 
called caspase-1, is responsible for the cleavage into active IL-ȕ (Wilson et 
al., 1994; Kronheim et al., 1992). There are two types of IL-1 receptors (IL-
1R) with the ability to bind IL-ȕ WKHVHDUH located on cell surfaces. Binding 
of IL-ȕ WR IL-1R type I induces a signal transduction resulting in biological 
effects whereas binding to IL-1R type II does not induce any signalling 
(Auron, 1998; Dinarello, 1996). The receptors can also be shed from the cell 
surface; binding of IL-ȕ WR WKHVe soluble receptors will not transduce any 
signalling. Instead, these receptors function as antagonists of IL-ȕ LQGXFHG
signalling (Dinarello, 1996). IL-ȕVLJQDOOLQJcan also be antagonized by IL-
1Ra, another member of the IL-1 family, which interacts with the same 
receptors as IL-ȕ DQG prevents the binding and signalling induced by IL-ȕ 
(Arend et al., 1998).  
Signalling pathways activated by IL-ȕ LQFOXGHQXFOHDU IDFWRUț% 1)ț%
and the mitogen-activated protein kinase (MAPK) pathways (Fan et al., 2007; 
Auron, 1998). IL-ȕinitiates SKRVSKRU\ODWLRQRILQKLELWRU\ț%,ț%OHDGLQJWR
UHOHDVHRI1)ț%IURP,ț%LQWRWKHQXFOHXVZKHUH1)ț%DFWVDVDWUDQVFULStion 
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factor (Tak & Firestein, 2001; Dinarello, 1996). The three main MAPK 
pathways activated by IL-ȕ LQYROYH the enzymes c-Jun NH2-terminal kinase 
(JNK), 38-kd protein kinase (p38), and extracellular signal-regulated kinase 
(ERK). The MAPKs activate transcription factors needed for expression of 
target genes (Fan et al., 2007; Auron, 1998). IL-ȕ signalling results in 
increased levels of several factors involved in the progression of OA such as 
other cytokines, chemokines, inducible nitric oxide synthase, phospholipase 
A2, cyclooxygenase 2, prostaglandins, and matrix-degrading enzymes (Kapoor 
et al., 2011; Goldring, 2000). 
TNF-Į 
TNF-Į LV detected in OA synovial fluid, synovial membrane, cartilage and 
subchondral bone (Kapoor et al., 2011; Martel-Pelletier et al., 1999). It 
activates pro-inflammatory and catabolic signalling pathways similar to those 
activated by IL-ȕ(Kapoor et al., 2011). Cleavage of membrane-bound TNF-Į
by the TNF-ĮFRQYHUWLQJHQ]\PHyields a biologically active, soluble TNF-Į
with the ability to bind receptors (Black et al., 1997; Aggarwal et al., 1985). 
Two cell-membrane bound receptors for TNF-Į71)UHFHSWRUW\SH,71)5,
or p55) and TNF receptor type II (TNFRII or p75) exist. TNFRI is the main 
receptor for TNF-Į LQ 2$ (Kapoor et al., 2011; Westacott & Sharif, 1996; 
Loetscher et al., 1990; Schall et al., 1990). TNF-Į FDQ DOVR ELQG WR VROXEOH
forms of these receptors resulting in inhibition of the TNF-Į VLJQDOOLQJ 
pathways (Higuchi & Aggarwal, 1992).  
1.4.3 Changes in articular cartilage during OA 
Dysregulation of chondrocyte function and remodelling of the ECM are 
features of OA leading to the destruction of articular cartilage (Loeser et al., 
2012; Goldring & Goldring, 2007). Chondrocytes in OA articular cartilage 
recapitulate a developmental program including phenotypical changes similar 
to the processes occurring during endochondral ossification (Tchetina, 2011; 
Sandell & Aigner, 2001). The early stages of OA include phenotypical changes 
such as  proliferation of progenitor cells and the late stages include terminal 
differentiation towards hypertrophy and apoptosis (Tchetina, 2011; Goldring & 
Goldring, 2010; Goldring & Goldring, 2007; Sandell & Aigner, 2001). 
Microscopic changes in OA articular cartilage include focal cell loss, 
superficial fibrillation, fissures, and erosions (Figure 8) (McIlwraith et al., 
2010; Pritzker & Aigner, 2010; Pritzker et al., 2006). Increased number and 
size of chondrocyte clusters, defined as multiple chondrocytes sharing 
pericellular matrix (Figure 8) (Pritzker & Aigner, 2010), is a characteristic of 
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OA cartilage and is assumed to be a result of chondrocyte proliferation towards 
hypertrophic cells synthesising type X collagen (Lotz et al., 2010).  
 
Figure 8. Light microscopic sections of equine articular cartilage stained with haematoxylin and 
eosin showing a) normal articular cartilage, b) fibrillated surface of articular cartilage, and c) 
focal cell loss and chondrocyte clusters (arrows). Scale bar: 100 m. 
Chondrocyte activity is altered during the different stages of OA. Anabolic 
activity leads to synthesis of ECM proteins, whereas catabolic activity leads to 
synthesis of matrix-degrading enzymes. Degradation of articular cartilage 
occurs when the anabolic activity cannot withstand the actions of the degrading 
enzymes. The degradation includes a gradual depletion of proteoglycans 
followed by disruption of the collagen network (Goldring & Goldring, 2010).  
Matrix-degrading enzymes such as a disintegrin and metallopeptidase with 
thrombospondin motifs (ADAMTS) and the MMPs are increased in OA 
cartilage and are responsible for degradation of the ECM (Troeberg & Nagase, 
2012; Heinegård & Saxne, 2011; Goldring & Goldring, 2010). Inflammatory 
stimuli such as cytokines induce the expression of matrix-degrading enzymes 
but these can also be induced by factors such as released matrix fragments 
(Goldring & Otero, 2011) and mechanical load (Kurz et al., 2005). The activity 
of MMPs and ADAMTS can be inhibited by tissue inhibitors of 
metallopeptidases (TIMPs) (Brew & Nagase, 2010). ADAMTS-4 and 5 are the 
major enzymes responsible for cleavage of aggrecan (Troeberg & Nagase, 
2012). MMP-13, also called collagenase-3, is the primary collagenase involved 
in the OA process (Troeberg & Nagase, 2012). MMP-13 is involved in the 
cleavage and denaturation of collagen type II (Billinghurst et al., 1997; 
Knäuper et al., 1996) but can also cleave aggrecan (Fosang et al., 1996). Other 
MMPs such as MMP-1 (collagenase-1), MMP-3 (stromelysin-1), MMP-8 
(collagenase-2), MMP-9 (gelatinase B) and MMP-14 (membrane-type-1 
MMP) are also involved in the degradation of cartilage, either by degradation 
of ECM directly or by activation of other matrix-degrading enzymes (Troeberg 
& Nagase, 2012; Billinghurst et al., 1997).  
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1.4.4 Diagnosis of equine OA 
Lameness examination of horses includes a physical palpation of the joint for 
pain, presence of swelling, heat and effusion of the joint, and evaluation of 
how the horse moves (Kidd et al., 2001; Trotter & McIlwraith, 1996). 
Subjective evaluation of the movements is routinely performed although 
objective methods for measuring asymmetry are emerging as a tool for 
lameness evaluation (Keegan, 2007). Flexion tests and intra-articular 
anaesthesia aid in the localisation of the specific joint responsible for the 
lameness (Kidd et al., 2001; Trotter & McIlwraith, 1996). The diagnosis of OA 
is based on different imaging techniques or arthroscopy. Radiology is the most 
common imaging technique. It is user-friendly and non-invasive, but the 
disadvantage is that early OA cannot be diagnosed due to the limited 
possibility to visualize non-mineralised tissue. Hence the technique cannot 
detect cartilage degeneration (Kidd et al., 2001; Park et al., 1996). Arthroscopy 
is an invasive method that allows direct visualisation of the joint structures and 
thereby detection of superficial cartilage fibrillation, fissures, and erosions 
(Kidd et al., 2001; Trotter & McIlwraith, 1996). 
Biomarkers 
The use of biomarkers as a tool for diagnosing OA is of interest in humans as 
well as equines. Soluble biomarkers in synovial fluid, blood or urine would be 
useful for the diagnosis of OA, classification of disease stages, prognosis, and 
monitoring of treatment response. The markers are often inflammatory 
mediators or molecules involved in ECM remodelling, degradation or repair 
(Bay-Jensen et al., 2016; Felson, 2014; Mobasheri, 2012). COMP and carboxy-
terminal cross-linked fragment of type II collagen (CTX-II) are the best 
validated biomarkers in humans (Bay-Jensen et al., 2016).  There is a need for 
further development and validation of biomarkers that accurately reflect the 
disease stages since the current biomarkers cannot differentiate normal ECM 
metabolism from pathological processes (Felson, 2014; Mobasheri, 2012).  
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2 Aims and hypotheses of the thesis 
The overall aim of the thesis was to follow cartilage changes resulting from 
cellular, genetic and molecular events during inflammation and development of 
cartilage. 
The overall hypothesis was that specific events occur at distinct time points 
that could be used to distinguish the different stages of OA. 
 
The aim of Paper I was to study the expression and localisation of proteins in 
developing equine cartilage comprising chondrocytes of different phenotypes. 
The hypothesis was that the phenotypes could be characterised based on 
expression of matrix molecules, Notch signalling components, and the stem 
cell-indicating factor Stro-1. 
 
The aim of Paper II was to follow the progression of inflammation in equine 
OA longitudinally. An in vitro inflammatory model was used to mimic the 
progression of inflammation in equine articular cartilage longitudinally to 
follow secretion of matrix molecules and inflammatory mediators induced by 
IL-ȕ 
The hypothesis was that matrix molecules and inflammatory mediators 
would be secreted in a time-dependent pattern, thereby allowing differentiation 
between early and late stage inflammation. 
 
The aim of Paper III was to follow the progression of inflammation in equine 
OA longitudinally. An in vitro inflammatory model was used to mimic the 
progression of inflammation in equine articular cartilage longitudinally to 
follow changes in gene expression induced by IL-ȕ 
The hypothesis was that gene expression of inflammatory mediators, matrix 
molecules, and phenotypic markers would change in a time-dependent pattern 
allowing differentiation between early and late stage inflammation. 
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3 Material and methods 
This section summarises the material and methods used in the studies included 
in this thesis. Detailed descriptions of the procedures are presented in each of 
the papers.  
3.1 Sample collection 
Collection of equine cartilage samples was approved by the Ethical Committee 
on Animal Experiments, Stockholm, Sweden (Dnr: N378/12) and the Ethical 
Committee on Animal Experiments, Uppsala, Sweden (Dnr: C62/13).  
3.1.1 Equine growth cartilage (Paper I) 
Equine osteochondral slabs of the distal radius were collected post-mortem 
from two foetuses (6.5 and 10 months gestational age) and from two young 
horses (2-day-old and 1-year-old) without clinical signs of orthopaedic disease 
and no macroscopic or microscopic lesions of the sampled joints. Growth-plate 
cartilage was sampled from all four individuals and articular cartilage was 
collected from the 6.5-month-old foetus, the 2-day-old and the 1-year-old 
horse. The slabs were fixed in 10% neutral buffered formalin, decalcified in 
3.4% (w/v) sodium formiate and 15.1% (v/v) formic acid, and embedded in 
paraffin. 
3.1.2 Equine articular cartilage explants (Papers II and III) 
Full-thickness cartilage explants (5-mm in diameter) were harvested aseptically 
from the distal third metacarpal bone post-mortem. The joints were 
macroscopically and microscopically normal and the horses had no clinical 
history of joint disease. Three horses with mean age 3 years were included in 
Paper II and 3 horses with mean age 6 years were included in Paper III. 
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3.2 Histology (Papers I-III) 
Paraffin-embedded tissues were sectioned and stained with haematoxylin and 
eosin (Papers I-III) for morphological evaluation; with picrosirius red (Paper I) 
for detection of collagen fibers; and safranin O (Paper II), and toluidine blue 
(Paper III) for evaluation of proteoglycan content. 
3.3 Immunohistochemistry (IHC) (Paper I) 
Protein localisation was delineated with IHC using primary antibodies for the 
surface antigen Stro-1, Notch signalling components Notch1, Jagged1, Dll4 
and Hes1, the Notch dysregulating protein EGFL7, and the matrix molecules 
COMP, fibromodulin, matrilin-1 and chondroadherin. The sections were 
digested with hyaluronidase and chondroitinase ABC. Endogenous peroxidase 
activity was quenched using hydrogen peroxide. Isotype controls were run in 
parallel with the primary antibodies and horseradish peroxidase (HRP)-
conjugated secondary antibodies were used for detection of bound primary 
antibodies. Visualization was done with a TSA-Direct Cy3 kit and nuclear 
staining with 4’,6-diamidino-2-phenylindole (DAPI) dihydrochloride. 
Subjective evaluation of the sections was performed using a Nikon Eclipse 
E600 fluorescence microscope and NIS Elements Basic Research software, 
version 3.22.11. The expression of Notch signalling components and Stro-1 
was graded subjectively from the staining as: absent, a few, many, or a 
majority of cells stained. The matrix molecules were graded as follows: absent, 
weak, moderate, or intense staining. 
3.4 Proximity ligation assay (PLA) (Paper I) 
Proximity between Notch1 and EGFL7 in equine growth cartilage was studied 
using Duolink™ in situ PLA technology. The sections were treated as for IHC 
until application of primary antibodies, and thereafter according to the 
manufacturer’s instructions. In brief, the two antibodies were added to the 
same section and proximity in location (<40 nm) resulted in amplification of a 
detectable fluorescent signal. Negative controls omitting one of the antibodies 
were run in parallel. Subjective evaluation of the sections was performed using 
a Nikon Eclipse E600 fluorescence microscope and NIS Elements Basic 
Research software, version 3.22.11. 
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3.5 Culture of articular cartilage explants (Papers II and III) 
In vitro studies of cartilage can be performed using different models such as 
chondrocytes grown in monolayer or three-dimensional pellet cultures. 
Explants from articular cartilage used in papers II and III allowed studies of 
chondrocytes within their surrounding ECM. The overall workflow is shown in 
figure 9 and the more specific details are described below. 
 
Figure 9. Workflow of cartilage explant culture including harvest of explants, adaption to culture 
conditions for 24-48 hours, stimulation with interleukin-ȕ (IL-ȕ or with culture media as 
unstimulated controls followed by harvest of explants and culture media. Culture media was 
collected at day 0, 3, 6, 9, 12, 15, 18, 22 and 25 (Paper II) or at day 0, 3, 9, 15, 21 and 27 (Paper 
III). Cartilage explants were harvested at day 25 (Paper II) or at day 0, 3, 9, 15, 21 and 27 (Paper 
III). This was followed by analysis of culture media and explants. 
Collection of cartilage explants
Adaption to culture conditions
 Unstimulated
 IL-1ɴ stimulated
Harvest
Culture media
MMP-13 (Papers II and III)
 GAG (Paper II)
 Collagen epitope C1,2C (Paper II)
Western blot for COMP (Paper II) 
 Proteomics (Paper II)
Explant
 Histology (Papers II and III)
Microarray (Paper III)
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3.5.1 Stimulation of cartilage explants (Papers II and III) 
Equine cartilage explants were incubated in cell culture media containing 
Dulbecco’s modified Eagle medium Nutrient Mixture F-12 supplemented with 
0.1 mg/ml cell culture-tested bovine serum albumin, 0.1 mg/ml ascorbic acid, 
and 4% penicillin/streptomycin for 24 h (Paper II) or 48 h (Paper III) at 37°C 
in 7% CO2/93% air to allow adaption to culturing conditions. 
The medium was removed from the explants and new cell culture medium 
containing 10 ng/ml recombinant equine IL-ȕ was added to the wells. 
Medium without IL-ȕZDVDGGHG WR WKHunstimulated controls. The explants 
were cultured at 37°C in 7% CO2/93% air and the medium was changed every 
third day. 
3.5.2 Harvest of cartilage explants and media (Papers II and III) 
Media were collected at day 0, 3, 6, 9, 12, 15, 18, 22 and 25 (Paper II) or at day 
0, 3, 9, 15, 21 and 27 (Paper III) after start of stimulation. The media were 
stored at -80°C until further analysis. Cartilage explants were harvested from 
one well containing medium with, and one well without, IL-ȕ DW  GD\V
(Paper II) or at all time points (Paper III). The explants were fixed in buffered 
formalin (Papers II and III) for 24h followed by paraffin embeddment. Two 
cartilage explants from each group were harvested at all time points (Paper III) 
and stored in sterile phosphate buffered saline (PBS) until isolation of 
ribonucleic acid (RNA). The total number of explants harvested from each well 
was weighed prior to different analyses. 
3.5.3 Analysis of culture media 
Analysis of MMP-13 in media (Papers II and III)  
MMP-13 content in culture media was measured using Fluorokine® E Human 
Active MMP-13 Fluorescent Assay. The assay was performed according to the 
manufacturer’s instructions using p-aminophenylmercuric acetate (APMA) 
which activates any potentially active forms of MMP-13. All samples were 
assayed in duplicate and the lower limit of detection was 8 pg/ml.  
GAG measurements (Paper II) 
Sulphated GAG content was measured in cell culture media using the 1,9-
Dimethylmethylene blue assay (Farndale et al., 1986). Samples were compared 
to a standard curve containing chondroitin sulphate, assayed in duplicate and 
normalized for cartilage wet weight. 
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Assay for collagen epitope C1,2C (Paper II) 
Cleavage of type I and type II collagens by collagenases generates a three-
quarter length carboxyterminal neoepitope fragment (C1, 2C) which was 
measured using a commercial enzyme-linked immunosorbent assay (ELISA). 
Samples were assayed in duplicate and the assay performed according to the 
manufacturer’s instructions. The limit of detection was 0.03 g/ml. 
Western blot for COMP (Paper II) 
COMP detection in culture media was done using an anti-bovine polyclonal 
antibody in a western blot. The samples were subjected to sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) according to the 
Laemmli protocol (Laemmli, 1970) and thereafter transferred to a 
nitrocellulose membrane. The membrane was blocked in skimmed milk, 
followed by incubation with the primary antibody and thereafter addition of the 
secondary antibody. Chemiluminescence detection reagents were used for 
detection of immunoreactive bands.  
3.5.4 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis 
of tandem mass tag (TMT) labelled culture media (Paper II)     
Shotgun proteomics was used to identify proteins released into the culture 
media of equine cartilage explants. Labelling with TMT-reagents was 
performed to quantify the levels of proteins and to compare the protein content 
in media from IL-ȕVWLPXODWHGDQGXQVWLPXODWHGH[SODQWVThe TMTs are tags 
composed of a reporter group, a mass-normalization spacer, and a chemically 
reactive group. The tags are chemically identical and have the same overall 
mass, but contain different isotopes. After fragmentation, the isotopes can be 
distinguished from each other and thereby allow relative quantification of the 
peptides (Dayon & Sanchez, 2012; Thompson et al., 2003). The overall 
workflow is shown in figure 10 and the more specific details are described 
below.  
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Figure 10. Workflow of proteomic analysis of culture media including sample preparation with 
tandem mass tag (TMT) labelling, liquid chromatography-tandem mass spectrometry (LC-
MS/MS) analysis, and data analysis. 
Sample preparation 
Culture media were concentrated on 3 kDa molecular weight cut-off filters and 
thereafter washed with water and 0.5 M triethyl ammonium bicarbonate until a 
pH >8 was reached. Sodium dodecyl sulphate was added to the samples and 
the proteins were reduced and alkylated prior to digestion with trypsin. A 
reference sample containing an aliquot of each sample was prepared in parallel 
with the samples. 
Digestion of samples
into peptides
TMT labelling
Fractionation
Separation 
(LC-column)
Ionising
peptides
Selection of 
precursor ions
(MS1)
Fragmentation Fragment ion
pattern
(MS2)
Protein 
identification
Quantification
Sa
m
pl
e
pr
ep
ar
at
io
n
LC
-M
S/
M
S 
an
al
ys
is
Da
ta
 a
na
ly
sis
LC
Retention time
MS1
m/z
MS2
m/z
Reporter ions
3 6 9 12 15 18 22
0
2
4
6
8
Control
IL-1E
Days
R
el
at
iv
e 
am
ou
nt
37 
TMT labelling 
Samples were labelled with TMT reagents 126, 127, 128, 129, 130 or 131 
according to the manufacturer’s instructions. The reactions were quenched and 
the labelled samples were combined and concentrated. This was followed by 
separation by Strong Cation Exchange Chromatography (SCX) on an ÄKTA 
purifier system. The peptides were acidified and injected into a 
PolySULFOETHYL A™ SCX column. The peptide-containing fractions were 
desalted on PepClean C18 columns and evaporated to dryness.  
LC-MS/MS analysis 
The fractions were analysed on an LTQ-Orbitrap-Velos mass spectrometer 
interfaced with an in-house constructed nano-LC column. The peptides were 
trapped on a pre-column and separated on a reverse-phase column. The LTQ-
Orbitrap-Velos was operated in data-dependent mode with one MS1 FTMS 
precursor ion scan followed by collision-induced dissociation (CID) and high-
energy collision dissociation (HCD) MS2 scans of the five most abundant 
doubly or triply protonated ions in each precursor scan. All samples were 
analysed a second time excluding m/z identified at 1% false discovery rate 
(FDR) on the first MS-analysis. 
Database search and TMT quantification 
Protein identification and relative quantification was performed using 
Proteome Discoverer version 1.3. Database searches were performed using the 
Mascot search engine against the ENSEMBL equine protein database version 
2.63 as well as the Uniref100 mammalian protein database. The TMT reporter 
ion intensities were divided by their reference reporter ion intensities yielding a 
ratio for each quantified peptide. Protein ratios were calculated as the median 
value for all the unique peptides for the given protein. No normalisation was 
applied and the albumin ratio was used to validate the variation in sample 
preparations. 
3.5.5 RNA isolation (Paper III) 
Isolation of RNA from the chondrocytes was performed using a modified 
method (Ali & Alman, 2012). The method included isolation of the 
chondrocytes from their surrounding ECM through mincing with a scalpel 
prior to enzymatic digestion using trypsin and collagenase. The cells were 
washed and filtered during the procedure and finally lysed with TRIzol® 
reagent. RNA was extracted by addition of 1-bromo-3-chloropropane followed 
by purification using a Qiagen RNeasy Mini Kit. Genomic DNA was removed 
using a Qiagen RNase-Free DNase Set and the samples were cleaned using a 
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Qiagen RNeasy MinElute Celanup Kit. All kits were used according to the 
manufacturer’s instruction. Concentration and integrity of RNA were analysed 
using a NanoDrop spectrophotometer and Agilent 2100 Bioanalyzer. 
3.5.6 Microarray (Paper III) 
Whole-transcriptome analysis was performed using the Affymetrix Equine 
Gene 1.0 ST Array. The chip on which the samples are analysed contain probes 
able to detect the entire equine transcriptome. The probes are selected across 
the entire genes and the array contains a median of 21 probes per gene. RNA 
from explants treated with and without IL-ȕ from all time points was analysed 
for the three horses in the study. 
Microarray expression analysis 
In brief, complementary DNA was generated from 2 ng of total RNA using a 
GeneChip® WT Pico Kit, followed by hybridization to a GeneChip® Equine 
Gene 1.0 ST Array. The arrays were washed and stained and finally scanned 
using the GeneChip® Scanner 3000 7G. 
Microarray data analysis 
The raw data were normalized in an Expression Console, provided by 
Affymetrix, using the robust multi-array average (RMA) method that was first 
suggested by Li and Wong in 2001 (Irizarry et al., 2003; Li & Wong, 2001). 
Subsequent analysis of the gene expression data was carried out in the 
statistical computing language R. A paired empirical Bayes moderated t-test 
was applied using the ‘limma’ package (Smyth, 2005; Smyth, 2004) to find 
differentially expressed genes between the IL-ȕ-stimulated and the 
unstimulated explants. To address the problem with multiple testing, the p-
values were adjusted using the method of Benjamini and Hochberg (Benjamini 
& Hochberg, 1995). Differences between the IL-ȕ VWLPXODWHG DQG the 
unstimulated explants was considered significant if the logarithmic fold change 
(log FC) was  1 or  -1 with p<0.05.  
The Database for Annotation, Visualization and Integrated Discovery 
(DAVID), v6.7 was used to identify enriched Gene Ontology (GO) terms and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the data sets 
(Huang et al., 2009; Huang et al., 2008). 
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4 Results and discussion 
This section briefly describes and discusses the results from the studies 
included in this thesis. Detailed information is presented in each of the 
individual papers. 
4.1 Paper I 
The matrix molecules COMP, fibromodulin, matrilin-1, and chondroadherin 
showed spatial changes in expression and localisation during maturation. The 
most prominent change was the relocalisation of COMP, fibromodulin and 
chondroadherin in the hypertrophic zone of the growth plate from their prenatal 
interterritorial to postnatal pericellular position.  This localisation change of the 
proteins was also observed in the other zones of the growth plate and in the 
articular cartilage; however, the shift occurred at different stages of maturation 
for the proteins. The studied matrix molecules are involved in collagen fibril 
formation and organisation of the ECM (Heinegård, 2009), with the 
pericellular matrix being the most important in the response to mechanical load 
(Guilak et al., 2006). Pericellular presence indicates an increased production of 
the molecules. The changes during maturation indicated involvement in the 
joint development, potentially induced by mechanical load after birth. It was 
not, however, possible to characterise the phenotypes of the chondrocytes 
based on the studied ECM molecules since the expression and localisation 
varied with the age of the horses rather, than with specificity to a certain 
phenotype.  
The localisation also changed during maturation of the Notch signalling 
components Notch1, Dll4, Hes1, the Notch dysregulating protein EGFL7 and 
the stem cell-indicating factor, Stro-1. Active Notch signalling is known to 
influence cell proliferation and inhibit chondrogenic differentiation (Karlsson 
et al., 2007; Dowthwaite et al., 2004; Watanabe et al., 2003). Thus the 
presence of Notch signalling components in equine growth cartilage suggests 
40 
that the studied proteins are involved in the development of equine joints. A 
juxtapositioning between Notch1 and EGFL7—detected as positive signals 
using in situ PLA—was seen in perivascular areas and hypertrophic cells. No 
clear association between EGFL7 and the target gene Hes1 was observed in 
our material. This may be because there were effects on other ligands or target 
genes than those studied. EGFL7 is also known to affect vessel infiltration 
(Parker et al., 2004); the presence of EGFL7 in perivascular chondrocytes and 
cells of the cartilage bone interface indicates a role for EGFL7 in vascular 
infiltration of equine growth cartilage. Hence EGFL7 could potentially be 
involved in the early stages of osteochondrosis latens in which there is a 
premature closure of vascular channels leading to chondronecrosis (Olstad et 
al., 2015). 
Notch1 was detected in all zones of the articular cartilage, a result 
consistent with studies of human articular cartilage (Grogan et al., 2009; 
Ustunel et al., 2008; Hiraoka et al., 2006). It also indicates that Notch1 is not 
exclusively expressed by progenitor cells and is therefore not an optimal 
marker for those cells. The stem cell-indicating factor Stro-1 was detected in 
all zones of the prenatal articular cartilage whereas the expression was 
restricted to the superficial and middle zones of the postnatal articular 
cartilage. Stro-1 was also detected in the zone of Ranvier (Figure 11) and in an 
area extending from the zone of Ranvier towards the articular cartilage along 
the perichondrium that has previously been suggested as a migration route for 
cells (Henriksson et al., 2013). This may strengthen Stro-1 positive cells as a 
potential source for repair of damaged cartilage.  
The zone of Ranvier has not previously been described in equine cartilage; 
in our study it was identified as an area comprising densely packed cells and in 
addition to Stro-1 also positive for EGFL7 and chondroadherin. It was further 
distinguishable from the surrounding tissue due to the absence of COMP. In 
summary, the markers used did not visualise exact phenotypic definition of the 
chondrocytes in the developmental growth cartilage. 
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Figure 11. Immunohistochemical staining of Stro-1 positive cells in the zone of Ranvier 
(encircled area) of a 10-month-old foetus. Positive labelling shown in yellow and nuclei in blue. 
Scale bar: 500 m. 
4.2 Paper II 
Equine cartilage explants stimulated with IL-ȕ in vitro during 25 days 
displayed a longitudinal release of molecules into the media. 127 proteins 
including ECM molecules and proteins related to inflammation were detected 
and quantified using quantitative proteomics.  
The release of GAGs into the media was highest day 3 and the release of 
collagen C1,2C peptides increased successively from day 18 to 25 in media 
from the IL-ȕVWLPXODWHGH[SODQWV. The release of these two correspond with 
the known degradation of the ECM during OA whereby proteoglycans are 
degraded prior to disruption of the collagen network (Goldring & Goldring, 
2010). MMP-13—the major collagen type II degrading enzyme (Billinghurst et 
al., 1997; Knäuper et al., 1996)—increased over time in media from the IL-ȕ
stimulated explants. Thus, it is presumably involved in the degradation of the 
collagen network also in this in vitro model. MMP-1 is another collagen 
degrading peptidase which also increased in media from IL-ȕ VWLPXODWHG
explants. MMP-3 is a peptidase known to be involved in the OA progression 
through activation of MMP-1 and MMP-13 (Troeberg & Nagase, 2012). 
MMP-3 increased in media from IL-ȕVWLPXODWHGH[SODQWV 
Inflammation was confirmed through detection of IL-6 (which has a 
regulatory role in OA with involvement in the IL-ȕ LQGXFHG PDWUL[
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degradation (Westacott & Sharif, 1996)), the chemokine (C-C motif) ligand 20 
(CCL20) (which is involved in pro-inflammatory and degradative responses in 
cartilage (Alaaeddine et al., 2015)), and through detection of SAA (which is 
involved in acute phase response triggered by IL-ȕ (de Seny et al., 2013)). 
Also components of the initial stages of the activation of the complement 
system were increased at days 3 and 6 in media from IL-ȕVWLPXODWHGH[SODQWV
indicating an inflammation related increase.  
Components of the ECM were released in a specific time pattern with early 
release of aggrecan, COMP, hyaluronan and proteoglycan link protein-1 
(HAPLN-1), chondroadherin, thrombospondin-1, and proteoglycan-4 (also 
called lubricin) (Figure 12). This was followed by release of collagen type 
XIIĮI and a late release of biglycan, fibromodulin, fibronectin, prolargin, and 
the collagens type II, VIĮIII, IXĮI and ;,Į, (Figure 12). The release of 
lumican, decorin and CILP consisted of two peaks (one early and one late) 
(Figure 12). This trend was also observed for fibromodulin and fibronectin, 
however the late peaks were the most prominent. The early release of 
aggrecan, identified by quantitative proteomics, was further confirmed by high 
levels of GAGs in media at day 3 and release of a semitryptic peptide 
(YDAICYTGEDF) originating from the G1 and G2 regions of the aggrecan 
molecule. Aggrecan is known to be degraded by aggrecanases in early stage 
OA (Caterson et al., 2000). The aggrecanases ADAMTS-4 and ADAMTS-5 
was not detected in our proteomic study. However ADAMTS may have been 
present, but undetected for several reasons. They may have been below the 
dynamic range of detectable concentrations; they may have been bound to the 
cartilage; they may not have been secreted at the studied time points; or, they 
may have had a short half-life in vitro.   
The release of matrix molecules involved in the organisation and 
stabilization of the collagenous network indicates that the collagen network is 
degraded in a time-dependent pattern. The dynamic changes observed in vitro 
may be useful for identifying components released during the progression of 
OA in vivo. If different time-specific components can be measured in synovial 
fluids from equine joints with OA, it may be possible to identify the duration of 
the joint pathology in that particular joint. These potential biomarkers could 
also aid in evaluating different treatments, including training regimes. 
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Figure 12. Molecules identified by quantitative proteomics during 22 days of IL-ȕVWLPXODWLRQ
Molecules released early in blue, released intermediate in red and released late in green. Levels 
measured by assays for collagen C1,2C peptide, matrix metallopeptidase-13 (MMP-13) and 
glycosaminoglycans (GAGs) are denoted in black. COMP, cartilage oligomeric matrix protein; 
HAPLN-1, hyaluronan and proteoglycan link protein-1; CILP, cartilage intermediate layer 
protein; COL, collagen. 
4.3 Paper III 
Stimulation of equine cartilage explants with IL-ȕ UHVXOWHG LQ VLJQLILFDQW
changes in gene expression during 27 days of culturing. Microarray analysis 
revealed differences related to inflammation, ECM and phenotype.  
IL-ȕ induced ECM degradation was seen as a decrease in toluidine blue 
staining, indicating a loss of proteoglycans in the stimulated explants. Results 
from the microarray analysis confirmed this as a downregulation of aggrecan 
(ACAN) from day 9, reaching significant downregulation by day 21. Collagen 
W\SH,,Į,(COL2A1), COL9A2 and COL9A3 were downregulated from day 15 
in stimulated explants, suggesting disruption of the collagenous network late in 
the culturing period. COL11A1 was downregulated at all time points after IL-
ȕ VWLPXODWLRQ, indicating that the collagenous network is affected already 
early after IL-ȕVWLPXODWLRQ. The ECM degradation was further confirmed as 
upregulation of matrix-degrading enzymes. MMP-1, -8 and -13 are collagen 
type II-degrading enzymes found in OA joints (Troeberg & Nagase, 2012; 
Goldring et al., 2011; Billinghurst et al., 1997; Knäuper et al., 1996; Reboul et 
al., 1996). Genes for these were upregulated in stimulated explants together 
with MMP2 and MMP3 involved in activation of other MMPs. This suggests 
increased synthesis of these enzymes and activation through MMP-2 and 
MMP-3 leading to subsequent degradation of the collagenous network. 
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ADAMTS4 was upregulated in stimulated explants during the whole culturing 
period and ADAMTS5 at day 27. Both of these genes express proteins that are 
considered to be the major aggrecan degrading enzymes in OA joints 
(Troeberg & Nagase, 2012; Bondeson et al., 2008). 
Induction of an inflammatory response after IL-ȕ VWLPXODWLRQ ZDV
identified by upregulation of IL1A, IL6 and LIF during the whole culturing 
period. IL-Į is a pro-inflammatory cytokine whereas IL-6 and LIF are 
regulatory cytokines. IL-6 is involved in upregulation of MMPs (Rowan et al., 
2001), downregulation of collagen type II (Porée et al., 2008) and induction of 
an acute phase response (Tilg et al., 1997). The protein LIF increases the 
production of IL-ȕ,/-6 and IL-8 (Henrotin et al., 1996; Villiger et al., 1993). 
The only anti-inflammatory cytokine differentially expressed in the stimulated 
and unstimulated explants was interleukin-1 receptor antagonist (IL1RN).  It 
was upregulated at day 3 in stimulated explants, indicating an attempt to inhibit 
the inflammatory actions by IL-ȕ early in the culturing period. Chemokines 
are other mediators of inflammation upregulated during the culturing period. 
Among these were chemokine (C-X-C motif) ligand 1 (CXCL1) and IL8 which 
induce chondrocyte hypertrophy and calcification and may contribute to the 
phenotypical changes occurring during the progression of OA (Merz et al., 
2003). The complement system is suggested to be a key component of OA 
pathogenesis (Wang et al., 2011) and the downregulation of the inhibitors C4 
binding protein alpha (C4BP), complement factor I (CFI), and CFH may affect 
the complement mediated inflammation. 
Non-collagenous molecules and SLRPs are important for the organisation 
and structure of the collagenous network (Heinegård, 2009). There was a 
downregulation in stimulated explants of the non-collagenous molecules 
COMP from day 9, matrilin-2 (MATN2) at days 3, 9 and 27 and CILP at all 
time points. The SLRPs extracellular matrix protein 2 (ECM2), lumican 
(LUM), osteomodulin (OMD), epiphycan (EPYC), mimecan (also called 
osteoglycin, OGN) and chondroadherin (CHAD) were downregulated at all 
time points, fibromodulin (FMOD) from day 9, biglycan (BGN) from day 15 
and decorin (DCN), asporin (ASPN) and prolargin (PRELP) at day 27 (Figure 
13). This may have affected the collagenous network during the inflammatory 
process in a time-dependent manner.    
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Figure 13. Gene expression of downregulated non-collagenous matrix molecules and 
proteoglycans in stimulated explants compared to unstimulated ones during the culturing period. 
Serglycin, SDC2, CILP, GPC6, ECM2, LUM, OMD, EPYC, OGN  and CHAD downregulated at 
all time points of IL-ȕVWLPXODWLRQ; COMP and FMOD from day 9; BGN from day 15; ACAN 
from day 21; and ASPN, PRELP, and DCN at day 27. 
Lubricin is important for boundary lubrication of articular joints where it 
reduces friction and chondrocyte apoptosis (Waller et al., 2013). The 
upregulation of lubricin (PRG4) during days 9 to 21 in the stimulated explants 
indicates an attempt to protect the articular cartilage. Lubricin has recently 
been suggested to interact with the receptor CD44 (Al-Sharif et al., 2015) 
which is the primary receptor for HA (Aruffo et al., 1990). CD44 was 
upregulated at all time points in the IL-ȕ stimulated explants, thereby 
enabling CD44 mediated interactions between chondrocytes and their 
surrounding ECM during the inflammatory process. The integrins are other 
receptors involved in interactions between cells and their surrounding ECM 
(Loeser, 2014). Upregulation of iQWHJULQ Į3 (ITGA3) from day 9 to 27 in 
stimulated explants; ITGA5 at day 15 to 27; and the downregulation of ITGA10 
and ITGA11 from day 9 to 27, may affect the interaction between cells and 
matrix with subsequent changes in proliferation, differentiation and matrix 
remodelling.  
Syndecans are transmembrane heparan sulphate proteoglycans with various 
biological functions such as binding to growth factors, acting as co-receptors, 
and mediating endocytosis (Iozzo & Schaefer, 2015; Choi et al., 2011). 
Syndecan 4 (SDC4) was upregulated and SDC2 was downregulated at all time 
points after IL-ȕ stimulation. Glypicans are other heparan sulphate 
proteoglycans anchored to the outer surface of the cell. Glypican 6 (GPC6) was 
downregulated at all time points in the IL-ȕ stimulated explants which may 
have affected the chondrocyte. The pericellular proteoglycan perlecan 
(HSPG2) was upregulated at days 3 and 9 in the IL-ȕ VWLPXODWHG H[SODQWV. 
Perlecan is involved in ECM stability, mechanotransduction, angiogenesis, 
chondrocyte metabolism and phenotypical changes that are important events 
during OA progression (Wilusz et al., 2012; Whitelock et al., 2008; Vincent et 
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al., 2007; Arikawa-Hirasawa et al., 1999; Aviezer et al., 1994). Perlecan can 
also enhance FGF signalling by formation of complexes with FGFs and FGF 
receptors (FGFRs) (Chuang et al., 2010). Enhancement of FGF2 signalling 
through FGFR1 leads to a catabolic response (Yan et al., 2011), whereas 
FGF18 signalling through FGFR3 initiates an anabolic one (Davidson et al., 
2005). CSPG4, a transmembrane cell surface proteoglycan upregulated at days 
15 and 21, is also involved in FGF signalling (Cattaruzza et al., 2013). 
Genes related to a chondrogenic phenotype include COMP, COL2A1, v-ets 
erythroblastosis virus E26 oncogene homolog (ERG), melanoma inhibitory 
activity (MIA), and ACAN (Richardson et al., 2015; Schroeppel et al., 2011). 
These were downregulated from day 9, 15, 15, 21, and 21 respectively. This 
indicates a chondrogenic phenotype at the early time points of the culturing 
period, that was lost at the late time points of IL-ȕ VWLPXODWLRQ. In addition 
FGF18, involved in chondrogenic differentiation of mesenchymal cells 
(Davidson et al., 2005), was upregulated from day 3 to 21. Upregulation of 
runt-related transcription factor 2 (RUNX2) (at days 15 and 27) and vascular 
endothelial growth factor A (VEGFA) (at days 15 and 21) indicates a transition 
towards hypertrophy at the late time points of stimulation. However, no 
evidence of a hypertrophic phenotype was detected histologically and there 
were no upregulation of COL10A1 suggesting that the 27 days of culturing was 
not sufficient time to change the chondrocytes into hypertrophic cells. 
Transition of chondrocytes into hypertrophy can be inhibited by sex 
determining region Y-box 9 (SOX9) (Akiyama et al., 2002; Zhao et al., 1997), 
and this gene was not differentially expressed between the stimulated and 
unstimulated explants. Notch signalling is involved in phenotypical changes 
including inhibition of differentiation towards chondrogenic cells (Chen et al., 
2013b; Karlsson et al., 2007; Watanabe et al., 2003). The receptor NOTCH1 
was upregulated at day 21 in the IL-ȕ VWLPXODWHG H[SODQWV, the target genes 
HES1 at days 21 and 27, and hairy/enhancer-of-split related with YRPW motif 
protein 2 (HEY2) from day 15. This indicate activation of Notch signalling 
potentially activated by the non-canonical ligand delta/notch-like EGF repeat 
containing (DNER) upregulated from day 15. 
The in vitro model shows time-dependent changes in gene expression 
related to inflammation, ECM, and phenotypical alterations of relevance for 
IL-ȕLQGXFHGLQIODPPDWLRQLQ2$ Knowledge about gene expression during 
inflammation is crucial in the search for unique biomarkers that can identify 
relevant anabolic and catabolic processes in the equine articular cartilage in 
vivo. 
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4.4 Papers II and III 
The combined studies of gene expression and protein release from equine 
articular cartilage explants will increase the knowledge of the events during IL-
ȕLQGXFHGLQIODPPation in articular cartilage. The release of a protein into the 
culture media, together with downregulated gene expression in the cartilage 
tissue, indicate a release of ECM proteins without new synthesis to compensate 
this loss. This was true for many ECM molecules such as the collagen types II, 
IX and XI. Release of aggrecan and COMP into culture media of stimulated 
explants was seen early in the culturing period, followed by a downregulation 
of gene expression. Protein release prior to downregulation of gene expression 
was also observed for decorin and prolargin; however, it occurred late in the 
culturing period. Downregulation of gene expression during the whole IL-ȕ
stimulation, and an early release of proteins into media, was observed for 
lumican, osteomodulin, epiphycan, chondroadherin and CILP. A 
downregulation of gene expression before release of protein into media was 
seen for fibromodulin and biglycan. A release of ECM proteins, combined with 
downregulated gene expression may lead to depletion of the molecules in the 
cartilage explants as a result of IL-ȕ VWLPXODWLRQ Lubricin, however, was 
released early into the culture media and followed by an upregulation of gene 
expression, which indicates an attempt to compensate for the loss of this 
important surface protein. 
The peptidases MMP-1, -3 and -13 were increased in culture media of 
stimulated explants and also upregulated at the gene level, indicating an IL-ȕ
induced production. This was also the case for the cytokine IL-6 and the 
chemokine CCL20. Release of ADAMTS was not detected in the culture 
media even though an early upregulation of gene expression was seen for 
ADAMTS1, 4, and 9. However, the upregulation indicates an involvement of 
these ADAMTS in the IL-ȕLQGXFHGLQIODPPDWLRQ 
In summary, IL-ȕLQGXFHVSURGXFWLRQRI,/-6, CCL20 and MMPs, seen as 
upregulation at the gene level and increased release of the gene products into 
culture media. Time-dependent release of many ECM molecules was observed 
together with downregulated gene expression, suggesting depletion of the 
proteins in articular cartilage without new synthesis during the inflammation.  
  
48 
  
49 
5 Conclusions 
¾ The ECM molecules COMP, fibromodulin, matrilin-1 and chondroadherin 
as well as the Notch signalling components show spatial changes in 
localisation in developing equine cartilage, suggesting their involvement in 
maturation of synovial joints. 
¾ Stro-1 positive cells detected in the zone of Ranvier, along the possible 
migration route, and in the articular cartilage suggest presence of cells with 
stem cell-like characteristics in equine cartilage.  
¾ It was not possible to characterise the phenotypes of the chondrocytes 
during maturation based on IHC of the ECM molecules. 
¾ Proteins related to inflammation and ECM were released into cell culture 
media of IL-ȕVWLPXODWHGH[SODQWVin a time-dependent pattern with a late 
release of components of the collagenous network. The majority of released 
ECM molecules showed a downregulation of gene expression, suggesting 
release without new synthesis to compensate the loss. 
¾ Gene expression of inflammatory mediators and matrix-degrading enzymes 
was upregulated in IL-ȕ VWLPXODWHG H[SODnts during the culturing period, 
confirming the catabolic effects of IL-ȕRQarticular cartilage. 
¾ Genes related to a chondrogenic phenotype were downregulated late in the 
culturing period of IL-ȕ stimulated explants and genes related to a 
hypertrophic phenotype were upregulated late in the culturing period. This 
suggests, a chondrogenic phenotype early with transition towards 
hypertrophy at the late time points of stimulation, however not reaching a 
morphology of hypertrophy during the 27 days of culturing. 
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6 Future research 
Increased knowledge about the cellular, genetic, and molecular events during 
the progression of the inflammation involved in OA is essential for diagnosis, 
prognosis and treatment of the disease. Studies using in vitro methods will 
provide knowledge applicable in clinical studies. The results achieved from 
this thesis can be used as a basis for further studies. 
¾ Relating the genes and proteins to different stages of OA can aid in 
diagnosis and prognosis of the disease. Evaluating the genes and proteins 
included in this thesis in articular cartilage and synovial fluid from OA-
affected joints will connect the in vitro results to in vivo conditions.  
¾ The inflammation in OA progression includes other inflammatory 
mediators than IL-ȕ. Hence in vitro studies with other mediators, e.g., 
TNF-Į,/-6 and IL-8, will be of value.  
¾ In vitro studies of co-cultures of cartilage and synovial membrane explants 
will further increase the knowledge about how inflammation affects the 
joint structures.  
¾ The in vitro model presented in this thesis is an important tool to evaluate 
effects of OA medical treatments prior to studies in vivo. Pharmacological 
substances can be tested in this model prior to testing in live animals. This 
would minimize the use of research animals and be of great value for 
animal welfare. 
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7 Sammanfattning på svenska 
Osteoartrit (OA) är en vanlig orsak till hälta hos hästar. Sjukdomen innefattar 
inflammation i leden samt successiv nedbrytning av ledbrosket, subkondral 
benskleros med mikrofrakturer, osteofyter och en inflammatoriskt förtjockad 
ledkapsel (synovit och kapsulit). Ledbrosket består av kondrocyter omgivna av 
ett extracellulärt matrix (ECM) som påverkas under sjukdomens förlopp. 
Progressionen av OA från tidigt till sent stadium innefattar nedbrytning och 
omstrukturering av ECM med kollaps av det kollagena nätverket samt 
fenotypiska förändringar i kondrocyterna. Inflammatoriska mediatorer såsom 
cytokiner påverkar initiering och progression av OA bland annat genom att öka 
mängden matrixnedbrytande enzymer. Klinisk diagnos av OA ställs oftast sent 
i sjukdomsförloppet då det redan finns irreversibla skador i ledens vävnader. 
Det är därför viktigt att öka kunskapen om sjukdomens förlopp för att utveckla 
metoder som kan diagnosticera sjukdomen i ett tidigt stadium då det går att 
stoppa det destruktiva förloppet i ledbrosket.  
Syftet med avhandlingen var att följa förändringar som sker i brosket vid 
dess normala utveckling samt vad som sker under tidsintervallet 0-27 dagar när 
inflammation induceras av cytokinen interleukin (IL)-ȕ. Ökad kunskap om 
hur celler, gener och molekyler förändras kan användas för att hitta markörer 
för tidig OA. Hypotesen var att det sker specifika händelser under broskets 
utveckling samt under inflammationsförloppet som skulle kunna användas för 
att identifiera tidiga stadier av OA före kollaps av ECM. 
I arbete I studerades lokalisationen av olika proteiner under broskets 
utveckling. Syftet var att karaktärisera kondrocyternas fenotyp samt dess 
omgivande ECM. Studien visade att uttrycket samt lokalisationen av 
matrixmolekyler förändras under broskets utveckling. Signalering via 
receptorn Notch1 är involverad vid utveckling av olika celltyper och för 
komponenter involverade i signaleringen sågs förändringar under broskets 
utveckling. Även lokalisationen av stamcellsmarkören Stro-1 förändrades. 
Resultaten i studien indikerar att de studerade proteinerna har betydelse för 
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broskets utveckling, men någon exakt definition av kondrocyternas fenotyp 
kunde inte göras med dessa proteiner. 
För att studera hur inflammation inducerad av cytokinen IL-ȕ SnYHUNDU
ledbrosket användes en in vitro-modell där ledbrosk stimuleras med IL-ȕ
Modellen innebär att intakt ledbrosk avlägsnas från ledytan och efter tillsatts av 
IL-ȕVWXGHUDV OHGEURVNHW samt dess omgivande medium vid olika tidpunkter. 
Detta sker för både IL-ȕVWLPXOHUDWOHGEURVNVDPWRVWLPXOHUDGHNRQWUROOHUI|U
att följa inflammationsförloppet som startas av IL-ȕ ,DUEHWH ,,NDUWODGHV de 
proteiner som utsöndras i mediet med hjälp av kvantitativ proteomik. 
Resultaten visade att proteiner relaterade till inflammation och ECM 
utsöndrades i ett tidsrelaterat mönster med kollaps av det kollagena nätverket 
efter 25 dagar. I arbete III studerades uttrycket av gener i brosket med hjälp av 
microarray. Gener relaterade till inflammation, ECM samt fenotyp förändrades 
under stimuleringstiden. Gener för inflammatoriska mediatorer som cytokiner 
och kemokiner uppreglerades vid IL-ȕ stimulering. Även gener för 
matrixnedbrytande enzym uppreglerades och gener för ett flertal ECM 
molekyler nedreglerades vid IL-ȕ stimulering. Gener relaterade till en 
kondrogen fenotyp var nedreglerade i slutet av stimuleringsperioden vilket 
indikerar att kondrocyternas fenotyp förändras under inflammationsförloppet. 
Sammanfattningsvis bidrar resultaten i avhandlingen till ökad kunskap om 
kondrocyter och dess omgivande matrix samt hur dessa påverkas av 
inflammationen under sjukdomsförloppet vid OA. En tidig förändring av 
ECM-molekyler, som i de senare tidsperioderna resulterade i det kollagena 
nätverkets kollaps, var tydlig. Resultaten från in vitro-modellen kan användas 
för att upptäcka nya potentiella kandidater avseende biomarkörer för tidig OA. 
Modellen är även användbar för att studera effekter av nya farmakologiska 
substanser och dessas potential att hejda sjukdomsförloppet vid OA utan att 
använda försöksdjur.  
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